Yun‐Chi Lu

454 total citations
16 papers, 356 citations indexed

About

Yun‐Chi Lu is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Biomaterials. According to data from OpenAlex, Yun‐Chi Lu has authored 16 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Biomaterials. Recurrent topics in Yun‐Chi Lu's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Nanoparticle-Based Drug Delivery (6 papers) and Glycosylation and Glycoproteins Research (4 papers). Yun‐Chi Lu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Nanoparticle-Based Drug Delivery (6 papers) and Glycosylation and Glycoproteins Research (4 papers). Yun‐Chi Lu collaborates with scholars based in Taiwan, United Kingdom and France. Yun‐Chi Lu's co-authors include Tian‐Lu Cheng, Chih-Hung Chuang, Wen-Wei Lin, Kai-Wen Cheng, Yi‐An Cheng, I‐Ju Chen, Ta-Chun Cheng, Yuan-Chin Hsieh, Jaw‐Yuan Wang and Chih-Hua Tseng and has published in prestigious journals such as Analytical Chemistry, Scientific Reports and Journal of Medicinal Chemistry.

In The Last Decade

Yun‐Chi Lu

15 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yun‐Chi Lu Taiwan	11	203	100	96	82	62	16	356
Yi‐An Cheng Taiwan	11	237 1.2×	114 1.1×	81 0.8×	73 0.9×	62 1.0×	17	413
Julia Mantaj United Kingdom	11	245 1.2×	135 1.4×	78 0.8×	44 0.5×	33 0.5×	19	498
Eun Ji Lee South Korea	13	156 0.8×	116 1.2×	35 0.4×	41 0.5×	76 1.2×	31	408
Sumayah Al-Mahmood Iraq	3	212 1.0×	173 1.7×	24 0.3×	47 0.6×	64 1.0×	11	421
Jin Pei China	11	166 0.8×	74 0.7×	51 0.5×	76 0.9×	62 1.0×	23	328
Qiuyi Choo Singapore	9	221 1.1×	129 1.3×	19 0.2×	38 0.5×	35 0.6×	10	442
Ming-Ching Hsieh United States	10	372 1.8×	43 0.4×	219 2.3×	37 0.5×	61 1.0×	17	538
Hongyu Tao China	9	251 1.2×	41 0.4×	27 0.3×	65 0.8×	67 1.1×	14	347
Pingping Wu China	16	196 1.0×	163 1.6×	20 0.2×	72 0.9×	68 1.1×	23	507
Wenjing Yu China	11	243 1.2×	50 0.5×	25 0.3×	126 1.5×	144 2.3×	32	481

Countries citing papers authored by Yun‐Chi Lu

Since Specialization

Citations

This map shows the geographic impact of Yun‐Chi Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yun‐Chi Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yun‐Chi Lu more than expected).

Fields of papers citing papers by Yun‐Chi Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yun‐Chi Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yun‐Chi Lu. The network helps show where Yun‐Chi Lu may publish in the future.

Co-authorship network of co-authors of Yun‐Chi Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Yun‐Chi Lu. A scholar is included among the top collaborators of Yun‐Chi Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yun‐Chi Lu. Yun‐Chi Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Lu, Yun‐Chi, et al.. (2025). Spatial‐hindrance‐based pro‐Adalimumab prevents anti‐idiotypic antibody interference in pharmacokinetic and therapeutic efficacy. Bioengineering & Translational Medicine. 10(5). e70015–e70015.

Lin, Wen-Wei, Shey-Cherng Tzou, I‐Ju Chen, et al.. (2021). Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice. Frontiers in Immunology. 12. 767868–767868. 14 indexed citations

Lin, Wen-Wei, et al.. (2021). Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy. Scientific Reports. 11(1). 7598–7598. 7 indexed citations

Lin, Wen-Wei, Yun‐Chi Lu, Chih-Hung Chuang, et al.. (2021). Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy. Scientific Reports. 11(1). 14846–14846. 10 indexed citations

Lu, Yun‐Chi, et al.. (2021). Development of a structure-based computational simulation to optimize the blocking efficacy of pro-antibodies. Chemical Science. 12(28). 9759–9769. 4 indexed citations

Lin, Wen-Wei, Yun‐Chi Lu, Chih-Hung Chuang, & Tian‐Lu Cheng. (2020). Ab locks for improving the selectivity and safety of antibody drugs. Journal of Biomedical Science. 27(1). 76–76. 30 indexed citations

Cheng, Yi‐An, Yun‐Ming Wang, Tian‐Lu Cheng, et al.. (2020). Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer. Journal of Nanobiotechnology. 18(1). 118–118. 13 indexed citations

Chen, I‐Ju, Yi‐An Cheng, Wen-Wei Lin, et al.. (2020). Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes. Acta Biomaterialia. 111. 386–397. 21 indexed citations

Cheng, Kai-Wen, Yuan-Chin Hsieh, Wen-Wei Lin, et al.. (2019). Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein. Scientific Reports. 9(1). 9931–9931. 8 indexed citations

10.

Cheng, Yi‐An, I‐Ju Chen, Yu-Cheng Su, et al.. (2019). Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer. Biomaterials Science. 7(8). 3404–3417. 28 indexed citations

11.

Lu, Yun‐Chi, Chih-Hung Chuang, Kuo‐Hsiang Chuang, et al.. (2019). Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy. PLoS Biology. 17(6). e3000286–e3000286. 26 indexed citations

12.

Cheng, Kai-Wen, Chih-Hua Tseng, Cherng‐Chyi Tzeng, et al.. (2018). Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. Pharmacological Research. 139. 41–49. 73 indexed citations

13.

Fang, Yi‐Ping, et al.. (2018). SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study. International Journal of Nanomedicine. Volume 13. 2789–2802. 33 indexed citations

14.

Cheng, Kai-Wen, Chih-Hua Tseng, Chia‐Ning Yang, et al.. (2017). Specific Inhibition of Bacterial β-Glucuronidase by Pyrazolo[4,3-c]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity. Journal of Medicinal Chemistry. 60(22). 9222–9238. 35 indexed citations

15.

Chen, I‐Ju, Chih-Hung Chuang, Yuan-Chin Hsieh, et al.. (2017). Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains. Scientific Reports. 7(1). 36 indexed citations

16.

Lin, Wen-Wei, Yuan-Chin Hsieh, Yi‐An Cheng, et al.. (2016). Optimization of an Anti-poly(ethylene glycol) (anti-PEG) Cell-Based Capture System To Quantify PEG and PEGylated Molecules. Analytical Chemistry. 88(24). 12371–12379. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact